ClinicalTrials.gg

Program

ertugliflozin

Also written as “Ertugliflozin 5 mg”, “Ertugliflozin” and “Ertugliflozin 15 mg”.

Its studies are mostly in Diabetes Mellitus, Type 2 · Fatty Liver · Renal Insufficiency, led by 3 companies.

Furthest: phase 4, since Oct 7, 201322 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck200 open or runningphase 3since Oct 7, 2013Oct 1, 2009none ahead
Getz Pharma11 open or runningphase 4since Nov 18, 2022Nov 18, 2022none ahead
Humanis Saglık Anonim Sirketi10 open or runningphase 1since Dec 3, 2025Dec 3, 2025none ahead

Also a collaborator on its studies: Pfizer.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 5 studies since Oct 1, 2009.

  1. Apr 27, 2010Phase 1 study in HealthyMerck · NCT01114568 · 12 enrolled
  2. May 19, 2010Phase 1 study in Diabetes Mellitus, Type 2Merck · NCT01127308 · 6 enrolled
  3. Oct 13, 2010Phase 1 study in Diabetes Mellitus, Type 2Merck · NCT01223339 · 24 enrolled
  4. Sep 20, 2013Phase 1 study in Renal InsufficiencyMerck · NCT01948986 · 36 enrolled
  5. Oct 7, 2013Phase 3 study in Diabetes Mellitus, Type 2Merck · NCT01958671 · 461 enrolled
  6. Nov 12, 20133 phase 3 studies in Diabetes Mellitus, Type 2Merck · NCT01986881, NCT01986855, NCT01999218
  7. Jan 9, 20142 phase 3 studies in Diabetes Mellitus, Type 2Merck · NCT02033889, NCT02036515
  8. Mar 25, 2014Phase 3 study in Diabetes Mellitus, Type 2Merck · NCT02099110 · 1,233 enrolled
  9. Apr 14, 2014Phase 1 study in Diabetes Mellitus, Type 2Merck · NCT02115347 · 16 enrolled
  10. Aug 25, 2014Phase 3 study in Diabetes Mellitus, Type 2Merck · NCT02226003 · 291 enrolled
  11. Dec 11, 2015Phase 3 study in Diabetes Mellitus, Type 2Merck · NCT02630706 · 506 enrolled
  12. Jul 11, 2019Phase 3 study in Diabetes Mellitus, Type 2Merck · NCT04029480 · 166 enrolled · United States, Belgium, Canada and more
  13. Nov 18, 2022Getz Pharma's first study: phase 4 study in Fatty LiverNew to Getz PharmaGetz Pharma · NCT05644717 · 164 planned · Pakistan
  14. Dec 3, 2025Humanis Saglık Anonim Sirketi's first study: phase 1 study in Diabetes Mellitus, Type 2New to Humanis Saglık Anonim SirketiHumanis Saglık Anonim Sirketi · NCT07266779 · 36 enrolled · India

TargetBeta

SLC5A2 →read by rule
“Sodium/glucose cotransporter 2 inhibitor; Sodium/glucose cotransporter 2 inhibitor”ChEMBL 37, by rule

Other programs on SLC5A2

ProgramCompanyFurthest phaseStudies
empagliflozinruleBoehringer Ingelheimphase 4142
dapagliflozinAstraZenecaphase 4133
EnavogliflozinruleDaewoong Pharmaceuticalphase 325
vicadrostatBoehringer Ingelheimphase 316
Empagliflozin/LinagliptinruleHumanis Saglık Anonim Sirketiphase 12

Studies

All 22 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07266779Diabetes Mellitus, Type 2 · India1CompletedHumanis Saglık Anonim SirketiSep 4, 202536
NCT05644717Fatty Liver · Pakistan4RecruitingGetz PharmaNov 1, 2025164
NCT04029480Diabetes Mellitus, Type 2 · United States, Belgium, Canada and more3CompletedMerckApr 11, 2025166
NCT02630706Diabetes Mellitus, Type 23CompletedMerckDec 27, 2017506
NCT02226003Diabetes Mellitus, Type 23CompletedMerckFeb 23, 2016291
NCT02115347Diabetes Mellitus, Type 21CompletedMerckJan 10, 201516
NCT02099110Diabetes Mellitus, Type 23CompletedMerckMay 26, 20161,233
NCT02036515Diabetes Mellitus, Type 23CompletedMerckJun 6, 2016464
NCT02033889Diabetes Mellitus, Type 23CompletedMerckAug 3, 2017621
NCT01999218Diabetes Mellitus, Type 23CompletedMerckApr 18, 20171,326
NCT01986881Diabetes Mellitus, Type 23CompletedMerckDec 27, 20198,246
NCT01986855Diabetes Mellitus, Type 23CompletedMerckSep 28, 2016468
NCT01958671Diabetes Mellitus, Type 23CompletedMerckJul 28, 2016461
NCT01948986Renal Insufficiency1CompletedMerckOct 6, 201436
NCT01223339Diabetes Mellitus, Type 21CompletedMerckFeb 201124
NCT01127308Diabetes Mellitus, Type 21CompletedMerckJul 20106
NCT01114568Healthy1CompletedMerckJun 201012
NCT01096667Diabetes Mellitus, Type 22CompletedMerckFeb 9, 2011194
NCT01059825Diabetes Mellitus, Type 22CompletedMerckJan 20, 2011375
NCT01054300Diabetes Mellitus, Type 21CompletedMerckApr 7, 201052
NCT01018823Healthy Volunteer1CompletedMerckMar 18, 201040
NCT00989079Diabetes Mellitus, Type 21CompletedMerckDec 11, 200924

How it is read

Names in the registry

  • “Ertugliflozin 5 mg”, 10 entries
  • “Ertugliflozin”, 8 entries
  • “Ertugliflozin 15 mg”, 5 entries
  • “Ertugliflozin 10 mg”, 4 entries
  • “Ertugliflozin 1 mg”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.